Universe Pharmaceuticals Inc. Class A Ordinary Shares (UPC)

FairStock Score: 45/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Universe Pharmaceuticals is a 216-employee Chinese drugmaker selling traditional Chinese medicine derivatives, largely for elderly chronic conditions and cold and flu. It is a specialty/generic healthcare business with no visible durable moat: syrups and pills can face competition, limited pricing power, and reliance on distribution. The numbers as of the 2026-10-13 close are sobering. The market cap is only $1.9 million, while the stock trades at $4.27. FairStock's P/E is -3.09, and P/B is 0.04—so the market values the equity at a tiny fraction of book value. That can signal deep pessimism or assets of questionable quality. Returns are negative: ROE -3.50% and ROCE -1.72%. The balance sheet has low reported leverage, with D/E 0.17, but Altman Z-Score 0.47 and Piotroski F-Score 0/9 point to serious financial fragility and poor fundamental momentum. Revenue and profit growth are listed as N/A, and there are only zero years of filed results, so no Lynch category can be computed; I cannot judge a growth trajectory from the supplied data. Beta 1.59 and a 52-week range of $2.00 to $17.96 suggest high volatility and a shattered prior price. FairStock Score 45/100 is middling at best. Graham would ask whether the discount to book compensates for continuing losses and uncertainty. Buffett would ask whether this business has a moat and consistent earning power. On the evidence given, it does not. The price may look statistically cheap, but weak returns, poor scores, and missing history make it speculative rather than a clear value opportunity.

In plain English: Universe Pharmaceuticals makes and sells traditional Chinese medicines in China, including products for older people's chronic conditions and colds and flu. The business looks weak: it is losing money, its financial health checks are poor, and it has very little public financial history. The share price is very low compared with its accounting value, but the losses and uncertainty mean it is not clearly a bargain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer